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Abstract 
Background: Urine based assays that can non-invasively detect bladder cancer (BCa) have the potential to reduce 
unnecessary and invasive procedures. The purpose of this study was to develop a multiplex immunoassay that can 
accurately and simultaneously monitor ten diagnostic urinary protein biomarkers for application as a non-invasive test 
for BCa detection.
Methods: A custom electrochemiluminescent multiplex assay was constructed (Meso Scale Diagnostics, LLC, 
Rockville, MD, USA) to detect the following urinary proteins; IL8, MMP9, MMP10, ANG, APOE, SDC1, A1AT, PAI1, CA9 
and VEGFA. Voided urine samples from two cohorts were collected prior to cystoscopy and samples were analyzed 
blinded to the clinical status of the participants. Means (±SD) and receiver operating characteristic (ROC) curve analy-
sis were used to compare assay performance and to assess the diagnostic accuracy of the diagnostic signature.
Results: Comparative diagnostic performance analyses revealed an AUROC value of 0.9258 for the multiplex assay 
and 0.9467 for the combination of the single-target ELISA assays (p = 0.625), so there was no loss of diagnostic utility 
for the MSD multiplex assay. Analysis of the independent 200-sample cohort using the multiplex assay achieved an 
overall diagnostic sensitivity of 0.85, specificity of 0.81, positive predictive value 0.82 and negative predictive value 
0.84.
Conclusions: It is technically feasible to simultaneously monitor complex urinary diagnostic signatures in a single 
assay without loss of performance. The described protein-based assay has the potential to be developed for the non-
invasive detection of BCa.
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Background
Urine based assays that can non-invasively detect bladder 
cancer (BCa) have the potential to improve the diagnosis 
of BCa and help to avoid unnecessary and invasive diag-
nostic procedures. As such, several urine-based commer-
cial molecular tests have been FDA-approved for BCa 
detection and surveillance. These tests include the meas-
urement of soluble proteins such as bladder tumor anti-
gen (BTA) [1], and nuclear matrix protein 22 (NMP22) 
[2, 3], proteins detected on fixed urothelial cells (Immu-
noCyt) [4], and chromosomal aberrations detected by 
fluorescent in situ hybridization (Urovysion) [5]. Because 
of their marginal detection performance, these urine-
based assays have a limited role in the management of 
patients at risk for BCa, thus, the search for non-invasive 
urine-based tests with clinical utility for BCa continues.
The advent of advanced molecular profiling tech-
niques has enabled the derivation of molecular signatures 
that hold promise for more accurate and individualized 
patient evaluation [6]. A number of molecular signature 
assays are now being incorporated into clinical practice 
[7, 8], but the assays employed to monitor multiple tar-
gets per sample are, to date, rather complex and thus, 
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We have previously coupled high throughput, discov-
ery-based technology (i.e., genomics and proteomics) 
with bioinformatics in order to derive diagnostic signa-
tures that show promise for the accurate detection of 
BCa in voided urine samples [9–12]. Integration of data 
and selection based on p value, fold change and availabil-
ity of antibodies resulted in a 14-protein biomarker panel 
for subsequent testing and refinement in independent 
cohorts. Using commercial ELISA assay kits directed at 
the biomarker panel, we performed three independent 
experiments. First, we analyzed voided urines from 127 
subjects (64 with BCa and 63 controls) and confirmed 
that 10 of the 14 biomarkers were significantly altered in 
BCa compared to controls [13–16]. Next, we reported 
the validation of the 10-biomarker diagnostic panel 
(IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, 
APOE, SDC1 and SERPINE1) in a large cohort of patients 
(n  =  308; 102 BCa and 206 controls) including con-
trols with diverse urologic conditions (e.g., urolithiasis, 
moderate-severe voiding symptoms, urinary tract infec-
tion and hematuria) [17]. Recently, an outside laboratory 
externally validated the 10-biomarker diagnostic panel 
in a large cohort of patients (n = 320; 183 BCa and 137 
controls) [18]. In this study, we investigated the feasibil-
ity of developing a multiplex assay that could accurately 
and simultaneously monitor the diagnostic biomarkers 
in an efficient format for potential clinical application. 
A custom multiplex assay, using MULTI-ARRAY® tech-
nology (Meso Scale Diagnostics, LLC), was constructed 
and the analytical performance was compared with data 
obtained from individual ELISA assays directed at each 
of the same ten urinary proteins.
The multiplex assay was then used to evaluate the diag-
nostic signature in an independent cohort to determine 
sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV).
Methods
Patients and specimen processing
Under Western Institutional Review Board approval (IRB 
#Rosser 2014-1), previously collected and banked voided 
urine samples were available for analysis. Voided urine 
samples were collected prior to cystoscopy in all BCa 
subjects and controls and samples were analyzed blinded 
to the clinical status of the participants, thus the study 
satisfies both PRoBE and STARD study design [19, 20]. 
Patients with known renal disease or documented renal 
insufficiency were excluded from the current study. The 
study consisted of two independent cohorts (Table  1); 
cohort #1 consisted of 62 subjects (29 with newly diag-
nosed BCa and 33 with no previous history of urothelia 
carcinoma, gross hematuria, active urinary tract infec-
tion or urolithiasis, i.e., controls) and cohort #2 consisted 
of 200 subjects (100 with newly diagnosed BCa and 100 
with no previous history of urothelia carcinoma, gross 
hematuria, active urinary tract infection or urolithiasis, 
i.e., controls). Controls for the two cohorts consisted of 
healthy volunteers and individuals with voiding symp-
toms or microscopic hematuria. All 62 subjects in cohort 
#1 had their urines analyzed by individual commercial 
ELISA kits directed towards the ten targets in addition to 
the MSD multiplex assays in order to compare and con-
trast the two diagnostic modalities. Cohort #2 was only 
analyzed by the multiplex assay. Clinical information 
Table 1 Demographic and clinical-pathologic characteristics of study cohorts
* Wilcoxon rank sum test
a Primary BCa; no patient with a history of BCa
b Voiding symptoms, microscopic hematuria
Cohort #1 P value* Cohort #2 P value*






Median age (range, years) 68 (51, 93) 50 (20, 81) <0.0001 70 (20, 89) 50.5 (18, 81) <0.0001
Male:female ratio 25:4 27:6 0.639 81:18 81:19 0.882
Clinical stage and grade
 Tis high-grade 3 (10.3 %) 4 (4.0 %)
 Ta low-grade 4 (13.8 %) 17 (17.0 %)
 Ta high-grade 6 (20.7 %) 11 (11.0 %)
 T1 low-grade 0 (0 %) 4 (4.0 %)
 T1 high-grade 3 (10.3 %) 22 (22.0 %)
 ≥T2 high-grade 13 (44.8 %) 42 (42.0 %)
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associated with these urine samples were queried from 
our database.
Each urine sample was centrifuged at 600×g 4  °C for 
5  min. The supernatant was decanted and aliquoted, 
while the urinary pellet was snap frozen. Both the super-
natant and pellet were stored at −80 °C prior to analysis. 
Aliquots of urine supernatants were thawed and analyzed 
for protein content using a Pierce 660-nm Protein Assay 
Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). 
Frozen aliquots of urine samples were thawed and pro-
tein content was measured using a Pierce 660-nm Pro-
tein Assay Kit (Thermo Fisher Scientific Inc., Waltham, 
MA, USA) and a microplate reader (Synergy HT, BioTek 
Instruments, Winooski, VT, USA). The relatively con-
stant production of creatinine, a non-enzymatically 
metabolite of creatine, makes urinary creatinine a useful 
tool for normalizing the levels of other molecules found 
in urine [21]. The concentration of urinary creatinine 
was measured using a commercially available enzymatic 
assay (Cat # KGE005 R&D Systems Inc., Minneapolis, 
MN, USA) according to the manufacturer’s instructions. 
Briefly, urine supernatants were treated with alkaline 
picrate solution, which when creatinine is present, yields 
an orange-red color. Intensity at 490 nm corresponds to 
the concentration of creatinine in the sample. Creatinine 
concentrations of unknown samples were calculated by 
comparison to a standard curve.
Commercial enzyme‑linked immunosorbent assays (ELISA)
Levels of human Interleukin 8 (IL8, Cat # ab46032 
Abcam), Matrix Metalloproteinase 9 (MMP9, Cat # 
DMP900 R&D Systems Inc.), Plasminogen Activator 
Inhibitor 1 (SERPINE1, Cat # EA-0207 Signosis Inc.), 
Vascular Endothelial Growth Factor A (VEGFA, Cat # 
100663 Abcam), Angiogenin (ANG, Cat # CK400 CellS-
ciences), Carbonic Anhydrase 9 (CA9, Cat # DCA900 
R&D Systems Inc.), Matrix Metalloproteinase 10 
(MMP10, Cat # DMP1000 R&D Systems Inc.), Apolipo-
protein E (APOE, Cat # KA 1031 Abnova), Syndecan 1 
(SDC1, Cat # ab46506 Abcam) and A1AT (SERPINA1, 
Cat # ab108799, Abcam) were monitored in urine sam-
ples using commercial enzyme-linked immunosorbent 
assays (ELISA) as previously reported [17]. Calibration 
curves were prepared using purified standards for each 
protein assessed. Curve fitting was accomplished by 
either linear or four-parameter logistic regression follow-
ing the manufacturer’s instructions.
MULTI‑ARRAY assay
A panel of commercially available monoclonal antibod-
ies against each of the ten biomarkers was screened pair-
wise and antibody pairs were selected from an unbiased 
screen using recombinant protein and normal pooled 
urine. The final monoclonal antibody pair (capture and 
detection) was selected based on sensitivity, specific-
ity, physical properties, and recognition of native pro-
tein. Detection monoclonal antibodies were labeled with 
ruthenium (SULFO-TAG™ NHS-Ester), according the 
manufacturer’ s instructions (Meso Scale Diagnostics, 
LLC, Rockville, MD, USA). The multiplex assay, using 
MULTI-SPOT® plates, is based on a proprietary com-
bination of electrochemiluminescence detection and 
patterned arrays [22]. Briefly, immobilized capture anti-
bodies were placed in 350–500  μm spots at the bottom 
of polypropylene 96-well plates to capture target pro-
teins (for details see; http://www.mesoscale.com/Cata-
logSystemWeb/WebRoot/). Each spot is coated with a 
different analyte capture antibody, in this case against 
IL8, MMP9, MMP10, ANG, APOE, SDC1, A1AT, PAI1, 
CA9 and VEGFA. The sandwich immunoassay complex 
that forms generates light when the instrument applies 
a voltage. Optics and a cooled-CCD camera then collect 
and quantitatively measure light emitted and processing 
algorithms convert the data into target concentrations. 
A seven point standard curve across the 4 log dynamic 
range of the assays was included in the current assay 
design.
Initial sample testing noted the need to dilute 7 of the 
10 biomarkers fourfold (IL8, MMP9, MMP10, APOE, 
PAI1, CA9 and VEGFA) and 3 of the 10 biomarkers 200-
fold (ANG, SDC1, A1AT) to ensure concentrations were 
within optimal range on the calibration curve. Thus, we 
elected to divide the ten biomarkers into two patterned 
array panels (Panel 1—IL8, MMP9, MMP10, VEGFA, 
CA9, APOE and PAI1 and Panel 2—A1AT, ANG and 
SDC1.
Urine samples were handled on ice and diluted with 
MSD Assay Diluent 37, designed to reduce the effects 
from heterophilic antibodies and other interferents. 
Samples and standards (50  μl) were loaded onto the 
MSD® plate in duplicate with a multichannel pipettor in 
order to reduce pipetting error and allowed to incubate 
for 2  h and then washed out. SULFO-TAG conjugated 
detection antibody (25  μl) was added to each well and 
allowed to incubate for 2 h and then washed out. Subse-
quently, the sandwich immunoassay complex that forms 
was incubated MSD Read Buffer (150  μl), the electro-
chemiluminescent substrate, and levels of electrochemi-
luminescent units were measured on the QuickPlex® 
SQ 120 (MSD) instrument. Standard curves were con-
structed using MSD Discovery Workbench® 4.0, which 
allows for the selection of multiple non-linear and linear 
equations to fit the standard curve. Optimal curve fits 
were determined by visual graph evaluation and com-
parison of Akaike’s information criteria (AIC) values 
[23].
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Data analysis
First, urinary concentrations of each of the ten bio-
markers were normalized using urinary creatinine 
concentration. Next, we compared the diagnostic abil-
ity associated with the combination of the individual 
commercial ELISA assays directed at our ten biomark-
ers versus the diagnostic ability of the multiplex assay, 
which encompassed these same ten biomarkers. Then 
we investigated the diagnostic performance of the mul-
tiplex assay in an independent cohort. Logistic regres-
sion analysis with BCa status (yes vs. no) as the response 
variable and the ten biomarkers as the explanatory vari-
ables was performed. The individual biomarkers were 
combined into a linear combination with the regression 
coefficients obtained in logistic regression as the weights, 
and the linear combination was used as a combined score 
for the detection of BCa. Cutoff thresholds were identi-
fied in cohort #1 and applied to the analysis of cohort #2. 
Then for a given cutoff threshold, we calculated the sen-
sitivity and specificity of the test. We generated a ROC 
curve by plotting values for sensitivity against the false-
positive rates (1-specificity) for various cutoff thresholds 
[24]. The relative ability of the combination of biomark-
ers to indicate BCa was estimated by calculating the area 
under the ROC curves (AUC), with a higher AUC indi-
cating a stronger predictor. We select the optimal cutoff 
value defined by the Youden index [25], i.e., the cutoff 
value that maximizes the sum of the sensitivity and the 
specificity. We estimated the sensitivity, specificity, PPV 
and NPV of the combination of biomarkers at the opti-
mal cutoff value. Statistical significance in this study was 
set at p < 0.05 and all reported p values were 2-sided. All 
analyses were performed using SAS software version 9.3 
(SAS Institute Inc., Cary, NC, USA).
Results
Multiplex assay characterization
The physical components, a library of capture and detec-
tion antibodies, and the secondary reagents for the 
MULTI-ARRAY technology, have undergone extensive 
optimization by the manufacturers for consistent imple-
mentation. Ranges for each analyte assay were evaluated 
by dilution of standards to determine upper ranges where 
high-end hook effect and apparent antibody saturation 
are avoided and lower ranges that are above detection 
limits. Lower limits of detection (LLOD) were calculated 
based on 2.5× the standard deviation of the background 
assessed across the plates run during sample testing. 
LLOD for each analyte in Panel 1 was 0.081  pg/ml IL8, 
38.4  pg/ml MMP9, 3.39  pg/ml MMP10, 0.030  pg/ml 
VEGFA, 2.13 pg/ml CA9, 236 pg/ml APOE and 1.97 pg/
ml PAI1 and in Panel 2 was 17.4  pg/ml A1AT, 0.13  pg/
ml ANG and 0.62 pg/ml SDC1, demonstrating sufficient 
sensitivity to detect proteins present in small amounts 
in voided urine samples. Intra assay precision was meas-
ured with acceptance criteria of a coefficient of variation 
(% CV) of less than 15.0. Median inter assay variability 
across all plates was also determined to be less than 15 % 
CV for each analyte. As the technology is an array, all 
components were checked for cross reactivity with other 
components in the antigen and antibody cocktails and 
confirmed to have less than 0.5 % cross reactivity. Lower 
limits of quantification (LLOQ) were estimated as being 
at the concentration with signals least three times over 
background and the lowest point of the 7-point standard 
curve where the back-fit regression recovered to within 
20  % of the known value and had %  CVs of less than 
20 %. The dilution linearity of five pooled urine samples 
was between 80 and 120 % for all analytes at the recom-
mended sample dilution factor, suggesting that there was 
not any interference due to the matrix.
Multiplex assay vs. individual ELISA assays
In order to test the robustness of the multiplex assay, 62 
urines samples (29 from BCa subjects) were monitored 
for the ten biomarkers using both the multiplex assay and 
the ten commercially available individual assays. Demo-
graphics and disease characteristics of cohort #1 are 
summarized in Table  1. Urinary concentrations of 7 of 
the 10 biomarkers were significantly elevated in patients 
with BCa compared to controls in both multiplex assay 
and individual ELISA assays (Table  2). A combinatorial 
analysis of all ten biomarkers using optimal cutoff val-
ues defined by Youden index calculations resulted in an 
AUROC (Fig.  1a) of 0.9258 (95  % CI 0.8559–0.9958) in 
the multiplex assay and 0.9467 (95 % CI 0.8944–0.9990) 
for the individual ELISA assays (p = 0.625). Thus, there 
was no difference between the diagnostic performances 
of the two formats. The multiplex assay achieved an 
overall sensitivity of 0.79, specificity of 0.97, PPV of 0.96 
and NPV of 0.84 for BCa classification. Table 3 provides 
AUROC for each biomarker and combination of the ten 
biomarkers tested in the multiplex assay and individual 
ELISA assay.
Validation of the multiplex assay
In order to validate the diagnostic performance of the 
assay in a larger cohort, the multiplex assay was applied 
to an independent cohort of 200 urine samples (100 from 
BCa subjects). Demographics and disease characteris-
tics of the cohort (cohort #2) are summarized in Table 1. 
In this validation cohort, urinary concentrations of 9 of 
the 10 biomarkers were significantly elevated in patients 
with BCa compared to controls (Table  4). Furthermore, 
the urinary concentrations of 3 of the 10 biomarkers (IL8, 
MMP10 and PAI1) were significantly elevated in patients 
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with high-grade BCa compared to low-grade BCa, while 
7 of the 10 biomarkers (IL8, MMP9, A1AT, ANG, VEGF, 
MMP10 and PAI1) were significantly elevated in patients 
with muscle invasive BCa (MIBC) compared to non-
muscle invasive BCa (NMIBC) (Table  4). Based on our 
prediction rule developed from cohort #1, the multiplex 
assay achieved an overall diagnostic sensitivity of 0.85 %, 
specificity of 0.81 %, PPV 0.82 % and NPV 0.84 % for the 
combination of the ten biomarkers (Fig. 1b). Table 5 pro-
vides AUROC and corresponding sensitivity, specificity, 
PPV and NPV values for all biomarkers tested.
Discussion
The data presented here demonstrates for the first time 
a multiplex immunoassay assay capable of measuring 
a unique diagnostic signature in voided urine samples 
from patients with BCa. The custom-designed multiplex 
assay showed excellent limits of detection in the low pg/
ml range and wide dynamic ranges up to at least 5000 pg/
ml. Specifically, each of the biomarkers analyzed (i.e., IL8, 
MMP9, MMP10, VEGFA, CA9, APOE, PAI1, A1AT and 
ANG) were present at higher levels in voided urines from 
BCa subjects compared to controls. The only biomarker 
that was not consistently elevated in the urines of BCa 
patients was SDC1. We have previously reported that 
while SDC1 is not always elevated in BCa urine samples 
relative to controls it can provide prognostic information 
based on its association with tumor grade and stage [26]. 
Though not statistically significant, mean values of SDC1 
were 60  % higher when comparing high-grade to low-
grade tumors and 110 % higher when comparing MIBC 
to NMIBC in this study.
We have reported the derivation and the validation 
of the urinary 10-biomarker BCa diagnostic signature 
in a number of studies with a total of over 800 subjects 
[13–18]. Recent work from our laboratory using quanti-
tative immunohistochemical staining techniques for the 
detection of the signature proteins has shown a strong 
association of expression and malignancy in human blad-
der tumor tissues [27]. Taken together, these data are the 
basis for a phased, methodical course to develop a robust 
multiplex diagnostic assay to assist in the non-invasive 
detection of BCa.
There is a growing demand for the integration of mul-
tiplex molecular signatures into single assays in order to 
obtain favorable assay properties such as reduced sam-
ple volume, decreased processing time, low cost analysis 
and low reagent consumption. Several multiplex protein 
measurement services are available (e.g., Sample Testing 
Services of Quansys Biosciences Inc.—microplate-based; 
Aushon Biosystems and SearchLight Assays Services—
microplate-based; Milliplex MAP—bead-based; and 
RayBiotech, Inc.—slide-based), and several studies have 
reported that multiplex ELISA procedures appear suita-
ble and reliable for tissue lysate and serum [28, 29]. While 
there are inherent, usually subtle differences between the 
various multiplex technologies, the overall approach and 
goals are the same; to construct a rapid, cost effective, 
and reliable immunoassay. The reliability of any immuno-
assay assay is due in part to the characteristics of specific 
capture and detection antibody pairs that are employed 
for the measurement of a specific protein. In particu-
lar, the PAI1 antibody pair used in the MULTI-ARRAY 
assay plate performed significantly better than the pair in 
the commercial ELISA kit (AUROC—0.8924 vs. 0.6740, 
respectively, p = 0.001). For inclusion in multiplex assays, 
selection of antibody pairs is driven by specificity for 
the target, but it also important that there should be no 
cross-reactivity with other proteins or antibodies in the 
assay milieu.
Table 2 Mean urinary (±SD) concentrations of  biomarkers assessed by  Multi-Array and  commercial ELISA assays 
in cohort #1
Multi‑Array® Commercial ELISA
Total bladder cancer  
(n = 29)
Total controls  
(n = 33)
p value Total bladder cancer 
(n = 29)
Total controls  
(n = 33)
p value
IL8 (pg/ml) 1429.3 ± 2897.7 123.1 ± 510.2 <0.0001 1155.7 ± 2179.7 33.3 ± 45.1 <0.0001
MMP9 (ng/ml) 24.4 ± 64.2 3.2 ± 10.6 <0.0001 4.8 ± 4.1 0.9 ± 1.4 <0.00001
A1AT (ng/ml) 4968.0 ± 8965.9 412.9 ± 513.9 0.0004 2362.2 ± 3682.4 218.8 ± 593.6 <0.0001
ANG (pg/ml) 8487.6 ± 25,979.1 816.3 ± 947.4 0.004 538.5 ± 863.9 174.0 ± 210.8 0.016
VEGFA (pg/ml) 357.7 ± 437.6 306.7 ± 467.9 0.481 294.5 ± 795.4 166.3 ± 137.5 0.631
CA9 (pg/ml) 35.9 ± 63.6 15.4 ± 22.6 0.828 2.3 ± 0.0 2.3 ± 0.0 1.000
MMP10 (pg/ml) 112.7 ± 196.9 26.1 ± 64.8 0.002 12.2 ± 43.7 4.1 ± 0.0 0.301
APOE (pg/ml) 210,368.9 ± 758,136.6 7316.1 ± 11,258.8 0.016 46,241.4 ± 38,121.7 30,000.0 ± 0.0 0.001
PAI1 (ng/ml) 5.2 ± 13.7 0.2 ± 1.0 <0.0001 0.1 ± 0.1 0.1 ± 0.0 0.065
SDC1 (pg/ml) 10,393.9 ± 12,279.5 13,477.3 ± 10,745.7 0.204 53,545.5 ± 98,390.1 103,803.3 ± 108,345.5 0.0001
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Fig. 1 Diagnostic performance of bladder cancer-associated molecular panel comprised of 10 biomarkers. a ROC curves were plotted to compare 
the performance characteristics of the MULTI-ARRAY® Assay (solid line) and the combined individual commercial ELISA assays (dotted line) in cohort 
#1 (62 subjects). Based on the area under the ROC curve (AUROC), Youden Index cutoff values that maximized the sum of sensitivity and specificity 
were determined for the combination of biomarkers. The MULTI-ARRAY® Assay achieved an overall sensitivity of 0.79 and specificity of 0.97 (AUROC 
0.9258). The combination of data from the individual target ELISA assays achieved an overall sensitivity of 0.82 and specificity of 0.97 (AUROC 
0.9467). b ROC curve to illustrate the performance characteristics of the MULTI-ARRAY® Assay in cohort #2 (200 subjects). The MULTI-ARRAY® assay 
achieved an overall sensitivity of 0.85 and specificity of 0.81 (AUROC 0.8880)
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The ability of each of the test biomarkers included in 
the multiplex assay to predict the presence of BCa was 
analyzed using nonparametric ROC analyses. Urinary 
PAI1 was the most accurate single biomarker with an 
AUROC of 0.8335 (95  % CI 0.8173–0.9097), a sensitiv-
ity of 74  %, specificity of 86  %, PPV of 85  % and NPV 
of 77  %, followed closely by urinary IL8—AUROC of 
0.8489 (Table 5). Many of the single biomarkers achieved 
respectable performance values, but the power of the 
multiplex approach is revealed when the data are com-
bined using a mathematical rule. The combination of data 
from all ten biomarkers measured on the multiplex assay 
achieved an AUROC of 0.8880 (95 % CI 0.8416–0.9344), 
with an overall sensitivity of 0.85, specificity of 0.81, 
PPV of 0.82 and NPV of 0.84 for BCa classification. The 
combinatorial power achieved using a biomarker panel 
approach attests to the heterogeneity of bladder lesions 
within the sampled population, and the importance of 
signatures that can overcome this heterogeneity. From a 
practical point of view, multiplex assays may also reduce 
the need for repeat sample testing due to more robust 
scoring systems.
The performance values achieved by the described 
multiplex assay far exceed those achieved by voided 
urine cytology or single biomarker tests for BCa detec-
tion, but as we refine and optimize the technical aspects 
of the assay and analyze additional samples, we expect 
to be able to further improve considerably assay perfor-
mance. Using 2002 Medicare data, we noted the unit 
cost for testing a voided urine cytology (VUC) sample of 
Table 3 Comparison of bladder cancer diagnostic biomarker performance in Multi-Array ® assay and commercial assays 
in cohort #1
Biomarker Area under the curve  
of Multi‑Array assay
Area under the curve  
of commercial assays
Difference P value
Commercial‑Multi‑Array 95 % confidence interval
IL-8 0.8673 0.9018 0.0345 (−0.0534, 0.1224) 0.442
MMP-9 0.8474 0.8443 −0.0031 (−0.0673, 0.0611) 0.924
A1AT 0.8443 0.8694 0.0251 (−0.0541, 0.1043) 0.535
Angiogenin 0.8109 0.7555 −0.0554 (−0.1503, 0.0395) 0.253
VEGF 0.6897 0.6228 −0.0669 (−0.2323, 0.0986) 0.428
CA-9 0.5705 0.6468 0.0763 (−0.0886, 0.2411) 0.364
MMP-10 0.7753 0.6792 −0.0961 (−0.2315, 0.0392) 0.164
APOE 0.7827 0.7043 −0.0784 (−0.2338, 0.0771) 0.323
PAI-1 0.8924 0.6740 −0.2184 (−0.3506, −0.0862) 0.001
Syndecan 0.5831 0.6301 0.0470 (−0.2118, 0.3058) 0.722
All 10 biomarkers 0.9258 0.9467 0.0209 (−0.0628, 0.1046) 0.625
Table 4 Mean urinary (±SD) concentrations and  clinical associations of  10 biomarkers in  cohort #2 assessed by  Multi-
Array assay
NMIBC non-muscle invasive bladder cancer, MIBC muscle invasive bladder cancer
* P < 0.05 comparing total bladder cancer to total controls
^ P < 0.05 comparing low-grade bladder cancer to high-grade bladder cancer
+ P < 0.05 comparing NMIBC to MIBC






NMIBC (58 %), n = 58 MIBC (42 %), n = 42 Total controls 
(50 %), n = 100
IL8 (pg/ml)*, ^, + 761.6 ± 804.4 348.3 ± 541.8 871.5 ± 829.4 593.2 ± 766.8 994.3 ± 805.9 122.8 ± 380.1
MMP9 (ng/ml)*, + 115.7 ± 392.9 26.0 ± 61.0 139.6 ± 438.4 89.0 ± 362.1 152.6 ± 433.6 2.8 ± 11.7
A1AT (ng/ml)*, + 4002.6 ± 7384.7 2961.5 ± 7204.7 4279.4 ± 7452.3 3949.8 ± 8302.9 4075.6 ± 5985.6 993.6 ± 2962.6
ANG (pg/ml)*, + 6501.0 ± 23,967.9 10,109.0 ± 42,456.3 5541.9 ± 16,201.7 6567.1 ± 27,404.6 6409.7 ± 18,520.3 619.0 ± 1093.1
VEGFA (pg/ml)*, + 1321.0 ± 1969.9 971.0 ± 1747.0 1414.1 ± 2025.0 1082.0 ± 1832.9 1651.1 ± 2122.9 570.4 ± 586.8
CA9 (pg/ml)* 168.6 ± 461.9 126.9 ± 398.6 179.7 ± 479.0 142.9 ± 409.9 204.1 ± 528.6 1.0 ± 0.0
MMP10 (pg/ml)*, ^, + 2576.3 ± 12,512.1 977.4 ± 3490.8 3001.3 ± 13,953.7 1444.5 ± 5444.0 4139.2 ± 18,234.5 5.0 ± 0.0
APOE (pg/ml)* 199,003.5 ± 587,474.7 202,108.4 ± 695,029.2 198,178.2 ± 560,516.7 266,463.1 ± 751,668.8 105,845.1 ± 180,362.0 21,654.7 ± 37,121.9
PAI1 (ng/ml)*, ^, + 26.2 ± 53.7 12.4 ± 43.8 29.9 ± 55.7 17.6 ± 47.8 38.1 ± 59.5 0.7 ± 3.8
SDC1 (pg/ml) 14,853.3 ± 43,824.9 9958.5 ± 9625.1 16,154.4 ± 49,048.9 10,814.6 ± 15,586.0 20,430.5 ± 65,153.2 10,459.7 ± 14,248.5
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$50.71 to be approximate ($55) to the cost of our multi-
plex assay. The benefits of the multiplex assay include (a) 
ease of performance and (b) rapidity of obtaining results. 
We are proposing a prospective study comparing head-
to-head VUC and our multiplex assay.
Clinically, accurate non-invasive BCa assays would have 
a clear impact on the clinical management of patients 
with BCa. The ultimate goal is to be able to detect BCa 
in a timely manner such that the patient can expect an 
improved survival as well as improved quality of life. For 
clinical implementation, a molecular test needs to be 
cost-effective, as well as accurate, especially if that test is 
to be used over a long period of follow-up as in the case 
for BCa. The detection of urinary proteins through mul-
tiplexed analyses has the potential to be relatively simple 
to perform and interpret, and affordable. We feel that the 
MSD multiplex assay described here is robust enough 
to deserve continued clinical development and to be the 
focus of a large prospective multiple center study.
Conclusion
Based on these encouraging preliminary data, we believe 
that the MSD multiplex assay for the non-invasive 
detection of BCa is a viable new platform that can be 
developed to be a simple, yet accurate diagnostic tool. 
Importantly, the assay has very sensitive levels of detec-
tion for the simultaneous monitoring of multiple protein 
targets yet can be readily implemented into a CLIA certi-
fied laboratory setting.
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